Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment.
星期二，Merck（紐交所：MRK）發佈了HERTHENA-Lung02第3期試驗patritumab deruxtecan在先前接受了EGFR酪氨酸激酶抑制劑（TKI）治療的局部晚期或轉移性EGFR突變非小細胞肺癌（NSCLC）患者中的頂線數據。
The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
該研究達到了無進展生存期（PFS）的主要終點，patritumab deruxtecan相比鉑金加pemetrexed誘導化療後的pemetrexed維持化療在統計學上顯示出顯著改善。
Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs.
儘管政府談判，美國人可能仍然不得不爲處方藥支付更多費用。
Overall survival (OS) data were immature at the time of the analysis, and the trial will continue to assess OS, a secondary endpoint.
在分析時，總生存期（OS）數據尚不成熟，試驗將繼續評估OS作爲一個次要終點。
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:DSNKY) and being jointly developed by Daiichi Sankyo and Merck.
Patritumab deruxtecan是一種由大塚製藥（場外交易：DSNKY）發現並與默克共同開發的具有特殊設計的以HER3爲靶的DXd抗體藥物聯苯胺（ADC）。
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.
HERTHENA-Lung02中觀察到的安全性與先前肺癌臨床試驗中觀察到的patritumab deruxtecan的安全性相一致，沒有發現新的安全信號。
The majority of interstitial lung disease (ILD) events were low-grade (grades 1 and 2). Two grade 5 ILD events were observed.
大多數間質性肺疾病（ILD）事件爲低度（1級和2級）。觀察到兩個5級ILD事件。
Recently, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
最近，Summit Therapeutics Inc.（納斯達克：SMMT）發佈了在中國由合作伙伴Akeso, Inc贊助的ivonescimab第3期HARMONi-2試驗的初步分析結果。
The trial evaluated monotherapy ivonescimab against Merck's Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression.
該試驗評估了單藥ivonescimab與Merck的Keytruda（pembrolizumab）在局部晚期或轉移性非小細胞肺癌患者中，其腫瘤具有陽性PD-L1表達。
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial's primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51.
ivonescimab單藥在該試驗的主要終點——無進展生存期方面顯示出了顯著的改善，相比單藥pembrolizumab，達到了0.51的風險比。
Price Action: MRK stock is up 0.39% at $118.42 during the premarket session at last check Tuesday.
股票行情: MRk股價於週二盤前交易時段上漲0.39%，報收於118.42美元。
- EssilorLuxottica And Meta Platforms Double Down On Smart Eyewear: Details.
- EssilorLuxottica和meta platforms加倍推動智能眼鏡：詳細信息。
譯文內容由第三人軟體翻譯。